GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Have a nice week! It’s hard to know exactly what change in Washington will mean for the health care industry starting next ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

GlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands, hoping to raise around £1 billion before spinning off its consumer healthcare business with Pfizer, according to ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough. The $14.75-per-share deal will add P2X3 antagonist ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

LEMSIP and other popular cold and flu tablets should be pulled from Britain’s shelves because they don’t work, experts have ...